United Therapeutics (STU:UTH) Total Debt per Share : €4.10 (As of Mar. 2025)

View and export this data going back to . Start your Free Trial

What is United Therapeutics Total Debt per Share?

€4.10 (As of Mar. 2025)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. United Therapeutics's Total Debt Per Share for the quarter that ended in Mar. 2025 was €4.10.

United Therapeutics Total Debt per Share Historical Data

The historical data trend for United Therapeutics's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

United Therapeutics Total Debt per Share Chart

United Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Debt per Share

Get a 7-Day Free Trial

14.78

15.70

16.41

13.65

6.39

United Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Debt per Share	Get a 7-Day Free Trial															12.49	10.46	8.08	6.39	4.10

United Therapeutics Total Debt per Share Calculation

United Therapeutics's Total Debt Per Share for the fiscal year that ended in Dec. 2024 is calculated as:

Total Debt Per Share	=	(Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation)	/	Shares Outstanding (EOP)
	=	(0	+	287)	/	45
	=	6.39

United Therapeutics's Total Debt Per Share for the quarter that ended in Mar. 2025 is calculated as:

Total Debt Per Share	=	(Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation)	/	Shares Outstanding (EOP)
	=	(0	+	185)	/	45
	=	4.10

United Therapeutics Total Debt per Share Related Terms

Thank you for viewing the detailed overview of United Therapeutics's Total Debt per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

United Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » United Therapeutics Corp (STU:UTH) » Definitions » Total Debt per Share

Comparable Companies

Traded in Other Exchanges

UTHR:USA UTH:Germany U2TH34:Brazil

Address

1000 Spring Street, Silver Spring, MD, USA, 20910

Website

https://www.unither.com

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

United Therapeutics Headlines

No Headlines